Opus Genetics LCA5 gene therapy shows 0.3 logMAR improvement in pediatric cohort; durable 18-month adult data

Opus Genetics, Inc.

Three pediatric participants (ages 16-17) showed group avg 0.3 logMAR visual acuity improvement and >1 log unit cone sensitivity improvement on FST.
All three pediatric participants improved on mobility test; microperimetry showed improved fixation in one evaluable participant.
Adult data (3 participants) show visual acuity improvements sustained through 18 months; therapy well-tolerated with no ocular SAEs.
Company expects to meet with FDA in Q4 2025 to discuss results and next steps for OPGx-LCA5 program.
No ocular serious adverse events or dose-limiting toxicities; all ocular AEs mild, anticipated, not related to study drug.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.